【24h】

Asthma

机译:哮喘

获取原文
获取原文并翻译 | 示例
           

摘要

Asthma is a heterogeneous group of conditions that result in recurrent, reversible bronchial obstruction. Although the disease can start at any age, the fi rst symptoms occur during childhood in most cases. Asthma has a strong genetic component, and genome-wide association studies have identifi ed variations in several genes that slightly increase the risk of disease. Asthma is often associated with increased susceptibility to infection with rhinoviruses and with changes in the composition of microbial communities colonising the airways, but whether these changes are a cause or consequence of the disease is unknown. There is currently no proven prevention strategy; however, the fi nding that exposure to microbial products in early life, particularly in farming environments, seems to be protective against asthma off ers hope that surrogates of such exposure could be used to prevent the disease. Genetic and immunological studies point to defective responses of lung resident cells, especially those associated with the mucosal epithelium, as crucial elements in the pathogenesis of asthma. Inhaled corticosteroids continue to be the mainstay for the treatment of mild and moderate asthma, but limited adherence to daily inhaled medication is a major obstacle to the success of such therapy. Severe asthma that is refractory to usual treatment continues to be a challenge, but new biological therapies, such as humanised antibodies against IgE, interleukin 5, and interleukin 13, off er hope to improve the quality of life and long-term prognosis of severe asthmatics with specifi c molecular phenotypes.
机译:哮喘是导致复发性,可逆性支气管阻塞的一系列异质性疾病。尽管该病可以在任何年龄开始,但多数情况下最先出现的症状是在儿童时期。哮喘具有很强的遗传成分,全基因组关联研究已发现几种基因的变异,这些变异会稍微增加患病的风险。哮喘通常与鼻病毒感染的易感性增加以及气道中微生物群落组成的变化有关,但是这些变化是疾病的原因还是后果尚不清楚。目前尚无行之有效的预防策略;但是,发现在生命早期,特别是在农业环境中,接触微生物产品似乎可以预防哮喘,因此人们希望可以使用这种接触的替代品来预防这种疾病。遗传学和免疫学研究表明,肺部驻留细胞的反应不良,尤其是与粘膜上皮相关的反应,是哮喘发病机理中的关键因素。吸入皮质类固醇仍然是治疗轻度和中度哮喘的主要手段,但是对每日吸入药物的依从性有限是该疗法成功的主要障碍。常规治疗难以耐受的严重哮喘仍然是一个挑战,但是新的生物疗法,例如针对IgE,白介素5和白介素13的人源化抗体,希望改善严重哮喘患者的生活质量和长期预后具有特定的分子表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号